• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (COVINGTON) -1018233 BARD® INLAY OPTIMA® URETERAL STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (COVINGTON) -1018233 BARD® INLAY OPTIMA® URETERAL STENT Back to Search Results
Model Number 788622
Health Effect - Clinical Code No Known Impact Or Consequence To Patient (2692)
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
The investigation is still in progress.Once the investigation is complete a supplemental report will be filed.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
 
Event or Problem Description
It was reported that a calcified formation was observed on the ureteral stent upon removal from the patient.
 
Additional Manufacturer Narrative
The reported event was confirmed after the visual evaluation.However, the root cause was unknown.The sample presented calcification on the stent's surface.For functional testing, the calcification was removed from the stent.It was submerged under water for a short time and when the stent was taken out from the water, it was noticed that the coating had been activated and was present on the stent.The device history record was reviewed and found nothing that could have caused or contributed to the reported event.The instructions for use state the following: "ureteral stents should be checked periodically for signs of encrustation and proper function.Periodic checks of the stent by cystoscopic and/or radiographic procedures are recommended at intervals deemed to be appropriate by the physician in consideration of the individual patients¿ condition and other patient specific factors.When long-term use is indicated, it is recommended that indwelling time not exceed 365 days.The stent is not intended as a permanent indwelling device." (b)(4).
 
Event or Problem Description
It was reported that a calcified formation was observed on the ureteral stent upon removal from the patient.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BARD® INLAY OPTIMA® URETERAL STENT
Common Device Name
URETERAL STENT
Manufacturer (Section D)
C.R. BARD, INC. (COVINGTON) -1018233
8195 industrial blvd
covington GA 30014
MDR Report Key6810256
Report Number1018233-2017-04370
Device Sequence Number16180659
Product Code FAD
UDI-Device Identifier00801741015748
UDI-Public(01)00801741015748
Combination Product (Y/N)N
Initial Reporter StateOH
Initial Reporter CountryUS
PMA/510(K) Number
K043193
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2017
Reporter Type Manufacturer
Report Source company representative,other
Initial Reporter Occupation Nurse
Type of Report Initial,Followup
Report Date (Section B) 10/06/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date09/13/2021
Device Model Number788622
Device Catalogue Number788622
Device Lot NumberNGBQ3063
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer08/11/2017
Initial Date Received by Manufacturer 08/01/2017
Supplement Date Received by Manufacturer09/20/2017
Initial Report FDA Received Date08/22/2017
Supplement Report FDA Received Date10/06/2017
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
-
-